Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth
Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock
Oppenheimer Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $26
Oppenheimer Initiates Larimar Therapeutics(LRMR.US) With Buy Rating, Announces Target Price $26
Hopeful Week For Insiders Who Bought US$540.7k Of Larimar Therapeutics Stock
Larimar Started at Outperform by Wedbush on FA Drug Candidate